These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20569190)

  • 21. Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouse.
    Zips D; Eicheler W; Brüchner K; Jackisch T; Geyer P; Petersen C; van der Kogel AJ; Baumann M
    Int J Radiat Biol; 2001 Dec; 77(12):1185-93. PubMed ID: 11747543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-cell-based computer simulation of the oxygen-dependent tumour response to irradiation.
    Harting C; Peschke P; Borkenstein K; Karger CP
    Phys Med Biol; 2007 Aug; 52(16):4775-89. PubMed ID: 17671335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Radiobiology of ablative dose in stereotactic irradiation: data update].
    Antoni DN; Burckel H; Josset É; Noël G; Mornex F
    Cancer Radiother; 2014; 18(4):264-9. PubMed ID: 24860988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in oxygenation status in intratumour total and quiescent cells following gamma-ray irradiation, tirapazamine administration, cisplatin injection and bleomycin treatment.
    Masunaga S; Ono K; Hori H; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y
    Br J Radiol; 2000 Sep; 73(873):978-86. PubMed ID: 11064652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ever-expanding role of HIF in tumour and stromal biology.
    LaGory EL; Giaccia AJ
    Nat Cell Biol; 2016 Apr; 18(4):356-65. PubMed ID: 27027486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIF-1 and tumour radiosensitivity.
    Moeller BJ; Dewhirst MW
    Br J Cancer; 2006 Jul; 95(1):1-5. PubMed ID: 16735998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
    Martínez-Sánchez G; Giuliani A
    J Exp Clin Cancer Res; 2007 Mar; 26(1):39-50. PubMed ID: 17550131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
    Van den Eynden GG; Van der Auwera I; Van Laere SJ; Colpaert CG; Turley H; Harris AL; van Dam P; Dirix LY; Vermeulen PB; Van Marck EA
    Br J Cancer; 2005 Nov; 93(10):1128-36. PubMed ID: 16251878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.
    Semenza GL
    Trends Pharmacol Sci; 2012 Apr; 33(4):207-14. PubMed ID: 22398146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.
    Meijer TW; Kaanders JH; Span PN; Bussink J
    Clin Cancer Res; 2012 Oct; 18(20):5585-94. PubMed ID: 23071360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model.
    Hendriksen EM; Span PN; Schuuring J; Peters JP; Sweep FC; van der Kogel AJ; Bussink J
    Microvasc Res; 2009 Mar; 77(2):96-103. PubMed ID: 19118564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor hypoxia in cancer therapy.
    Brown JM
    Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
    Patiar S; Harris AL
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of hypoxia-activated prodrugs in cancer therapy.
    Denny WA
    Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
    Carmeliet P; Dor Y; Herbert JM; Fukumura D; Brusselmans K; Dewerchin M; Neeman M; Bono F; Abramovitch R; Maxwell P; Koch CJ; Ratcliffe P; Moons L; Jain RK; Collen D; Keshert E
    Nature; 1998 Jul; 394(6692):485-90. PubMed ID: 9697772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
    Otrock ZK; Hatoum HA; Awada AH; Ishak RS; Shamseddine AI
    Crit Rev Oncol Hematol; 2009 May; 70(2):93-102. PubMed ID: 19186072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
    Dewhirst MW
    Cancer Res; 2007 Feb; 67(3):854-5. PubMed ID: 17283112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.
    Krause M; Schütze C; Petersen C; Pimentel N; Hessel F; Harstrick A; Baumann M
    Radiother Oncol; 2005 Feb; 74(2):109-15. PubMed ID: 15734198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment.
    Moeller BJ; Richardson RA; Dewhirst MW
    Cancer Metastasis Rev; 2007 Jun; 26(2):241-8. PubMed ID: 17440683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia, notch signalling, and prostate cancer.
    Marignol L; Rivera-Figueroa K; Lynch T; Hollywood D
    Nat Rev Urol; 2013 Jul; 10(7):405-13. PubMed ID: 23712204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.